Cytarabine (Cytosar)

From HemOnc.org - A Hematology Oncology Wiki
Jump to: navigation, search

General information

Class/mechanism: Pyrimidine analog, mimics cytosine. Converted intracellularly into cytarabine-5-triphosphate (ara-CTP). Exact mechanism of action not known; believed to inhibit DNA polymerase, incorporate into DNA and RNA, and kill cells undergoing DNA synthesis (S-phase) and sometimes block cells from progressing from the G1 phase to the S-phase.[1][2]
Route: IV, IT, SC
Extravasation: irritant or neutral, depending on reference

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

  • June 1969: initial FDA approval

Also known as

  • Generic names: Ara-C, arabinosylcytosine, arabinofuranosyl cytidine, cytosine arabinoside
  • Brand names:
Synonyms
Alcysten Alexan ARA Arabine Arabitin Aracitin Aracytin Aracytine
Citagenin Citaloxan Citarabin Citarabina Citarabins Citarax Cylocide Cytarabin
Cytarabins Cytarabinum Cytarbel Cytarine Cytosar Cytosar-U Cytrosar Depocyt
Depocyte Erbabin Erpalfa Fauldcita Groven Ifarab Iretin Laracit
Medsara Novutrax Remcyta Starasid Tabin Tabine Udicil

References

  1. 1.0 1.1 Cytarabine (Cytosar) package insert
  2. Cytarabine (Cytosar) package insert (locally hosted backup)
  3. Cytarabine (Cytosar) patient drug information (Chemocare)
  4. Cytarabine (Cytosar) patient drug information (UpToDate)